US adverse drug reaction surveillance 1989-1994

Area of Science:

• Pharmacovigilance and Drug Safety
• Regulatory Science
• Public Health Surveillance

Background:

• Adverse drug reaction (ADR) surveillance is crucial for identifying new pharmaceutical safety concerns.
• The US Federal Food and Drug Administration (FDA) actively encourages reporting from healthcare professionals and manufacturers.
• Increased reporting rates signal enhanced engagement in drug safety monitoring.

Purpose of the Study:

• To analyze trends in ADR reporting to the FDA from 1989 to 1994.
• To characterize the origin, type of reaction, and drugs involved in reported ADRs.
• To discuss the utility and constraints of the FDA's ADR surveillance system.

Main Methods:

• Analysis of ADR reports submitted to the FDA between 1989 and 1994.
• Categorization of reports based on origin, reaction type, and specific drugs.
• Qualitative assessment of the uses and limitations of the surveillance data.

Main Results:

• A significant increase in ADR reporting was observed, more than doubling over the five-year period (1989-1993) and continuing into 1994.
• A total of 421,491 ADR reports were received during 1989-1993.
• The majority of reports originated from health professionals, often submitted via pharmaceutical manufacturers; approximately 5% of reports concerned serious reactions to new drugs.

Conclusions:

• The FDA's efforts to stimulate ADR reporting have been successful, leading to a substantial increase in data.
• The surveillance system provides valuable insights into drug safety, although its limitations must be considered.
• Continued monitoring and analysis of ADRs are essential for ensuring pharmaceutical safety and informing regulatory actions.